<DOC>
	<DOCNO>NCT01237340</DOCNO>
	<brief_summary>To assess immunogenicity Saizen® solution injection adult subject document Growth Hormone Deficiency ( GHD ) .</brief_summary>
	<brief_title>Saizen® Solution Injection Adult Growth Hormone Deficiency ( GHD ) Immunogenicity Study</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Adult male female subject , 1860 year age , inclusive , time informed consent sign Subjects confirm adult GHD Subjects growth hormone ( GH ) treatmentnaive receive Saizen® ( freezedried formulation ) pediatric GHD ( PGHD ) , currently receive Saizen® freezedried formulation adult GHD ( AGHD ) Subjects bind antibodynegative ( BAbs ) screen Subjects evidence concomitant disease , intercurrent illness , resultant therapy would interfere subject compliance , evaluation study result , compromise safety subject Female subject childbearing potential negative serum pregnancy test screen visit ( schedule visit study ) Subjects willing comply procedure study Subjects willing sign Independent Ethics Committee/Institutional Review Board approve inform consent form Other protocoldefined inclusion criterion may apply Subjects currently receive previously receive treatment adult GHD indication , include PGHD , commercial GH product Saizen® freezedried formulation Subjects chronic underlying disease within 6 month prior screen concomitant medication ( ) opinion investigator would exclude subject trial Subjects significant renal impairment Subjects diabetes mellitus Subjects immunosuppressed Subjects current malignancy history malignancy ( exclude fullytreated basal cell carcinoma ) Subjects participate another study receive investigational drug within 30 day prior screen visit Subjects clinically significant abnormal laboratory value ( ) Subjects know hypersensitivity allergy exogenous human GH excipients phenol , bacteriostatic agent Saizen® solution injection Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Adult Growth Hormone Deficiency ( AGHD )</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>growth hormone</keyword>
	<keyword>antibody</keyword>
	<keyword>GH biomarkers</keyword>
	<keyword>IGF-I</keyword>
</DOC>